pf-06252616
mAbexperimental
Clinical trial activity
4 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Jun 1, 2012 (NCT01616277)
Timeline
Indications
Mechanism of action
- Growth/differentiation factor 8INHIBITOR
MSTN inhibitor
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Also known as
- pf 06252616
- pf-06252616
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02907619 | Phase 2 | Oct 13, 2016 | Pfizer |
| NCT02841267 | Phase 1/Phase 2 (Phase 2) | Jul 1, 2016 | Hugo W. Moser Research Institute at Kennedy Krieger, Inc., Pfizer |
| NCT02310763 | Phase 2 | Nov 24, 2014 | Pfizer |
| NCT01616277 | Phase 1 | Jun 1, 2012 | Pfizer |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Pfizer | For profit | 4 | 3 | 2 | 2012 |
| Hugo W. Moser Research Institute at Kennedy Krieger, Inc. | Academic/Hospital | 1 | 1 | 1 | 2016 |
2 organizations
Page 1 / 1